Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Baxter International Inc.'s published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $11.8B | |
|---|---|---|
| Revenue (ttm) | 11.5B | |
| Net income (ttm) | -1.1B | |
| EPS (ttm) | -$2.06 | |
| Shares out | 517M | |
| P/E (forward) | 11.2x | |
| Dividend | $0.04 (0.16%) | |
| Volume | 10,873,738 | |
| Beta | 0.65 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $12.15B | $10.06B | $10.36B | $10.64B | $11.24B | -1.9% |
| Gross profit | $4.72B | $3.55B | $4.15B | $3.98B | $3.38B | -8.0% |
| Operating income | $1.35B | $-2.85B | $707.0M | $14.0M | $-308.0M | — |
| Net income | $1.28B | $-2.43B | $2.66B | $-649.0M | $-957.0M | — |
| EPS (diluted) | $2.53 | $-4.83 | $5.23 | $-1.27 | $-1.87 | — |
| EBITDA | $2.19B | $-1.76B | $1.73B | $1.12B | $766.0M | -23.1% |
| R&D | $531.0M | $450.0M | $518.0M | $590.0M | $518.0M | -0.6% |
| SG&A | $2.85B | $3.10B | $2.95B | $2.97B | $2.89B | +0.4% |
Recent company headlines from major financial publishers.
Under the base path, Baxter delivers gradual operational improvements where operating margins normalize toward historical levels and international healthcare tenders sustain volume demand. Shares reach $26.92 with an estimated return of 18.1% at an assigned likelihood of 45.0%. Confirmation requires meeting forward consensus adjusted diluted earnings targets.
The bull path envisions accelerated supply chain streamlining that restores operating profitability toward sector benchmarks, enabling rapid debt repayment and multiple expansion. Under this outcome, shares reach $35.73 delivering a return of 56.7% with a probability of 25.0%. Confirmation would appear through consecutive quarterly margin beats.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 5.8% | $30.9 | $30.9 | $30.9 | $30.9 | $30.9 |
| 6.8% | $28.8 | $28.8 | $28.8 | $28.8 | $28.8 |
| 7.8% | $26.9 | $26.9 | $26.9 | $26.9 | $26.9 |
| 8.8% | $25.1 | $25.1 | $25.1 | $25.1 | $25.1 |
| 9.8% | $23.4 | $23.4 | $23.4 | $23.4 | $23.4 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
